Yahoo · Sep 23, 2026
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
LQ
NASDAQ · LQDA
Liquidia Corporation
Healthcare · Biotechnology
$28.64
Up+$0.65 (+2.32%)
Updated Oct 4, 2026, 1:37 AM
SID Score
4.5/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 2.79B
- P/E ratio
- -23.12
- Dividend yield
- 0.00%
- 52-week range
- $22.31 – $93.61
- Volume
- 8.4M
- Avg. volume
- 2.44M
Price performance · LQDA
LQDA price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
LQDA closed at $28.64 after 19 trading sessions, down 57.68% for the selected period.
- Last close
- $28.64
- Period change
- -57.68%
- Period low
- $27.99
- Period high
- $73.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $26.69 | $29.1794 | $26.31 | $28.64 | 8.4M |
| Oct 1, 2026 | $23.96 | $28.10 | $22.31 | $27.99 | 21.57M |
| Sep 30, 2026 | $70.54 | $71.93 | $29.86 | $30.26 | 22.95M |
| Sep 29, 2026 | $72.49 | $73.145 | $68.74 | $70.69 | 1.53M |
| Sep 28, 2026 | $68.05 | $74.74 | $67.655 | $73.67 | 1.21M |
| Sep 25, 2026 | $71.60 | $71.805 | $67.545 | $68.43 | 967.53K |
| Sep 24, 2026 | $67.04 | $71.41 | $66.75 | $70.95 | 1.03M |
| Sep 23, 2026 | $68.60 | $68.60 | $67.10 | $67.49 | 766.18K |
| Sep 22, 2026 | $66.59 | $68.76 | $66.00 | $68.64 | 1.14M |
| Sep 21, 2026 | $67.18 | $67.41 | $65.74 | $66.43 | 1.01M |
| Sep 18, 2026 | $68.08 | $68.72 | $66.57 | $66.88 | 3.9M |
| Sep 17, 2026 | $69.51 | $70.81 | $67.41 | $68.39 | 1.08M |
| Sep 16, 2026 | $65.67 | $69.87 | $65.34 | $68.45 | 1.3M |
| Sep 15, 2026 | $65.31 | $65.93 | $62.86 | $65.72 | 1.37M |
| Sep 14, 2026 | $66.79 | $66.895 | $65.1301 | $65.305 | 1.07M |
| Sep 11, 2026 | $68.66 | $69.9399 | $66.68 | $66.74 | 778.8K |
| Sep 10, 2026 | $67.87 | $68.35 | $66.62 | $67.85 | 955.03K |
| Sep 9, 2026 | $67.39 | $69.385 | $67.3501 | $69.12 | 997.25K |
| Sep 8, 2026 | $68.00 | $69.21 | $67.07 | $67.68 | 1.33M |
Latest LQDA news
The latest Smart Investors Daily articles mentioning LQDA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LQDA research
Overview
Company profile and research snapshot.
Company profile
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.33
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 2, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 1, 2026 | BTIG | Neutral | — |
| Oct 1, 2026 | Needham | Buy | — |
| Oct 1, 2026 | Raymond James | Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Sep 19, 2026
Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Quality
Liquidia (LQDA) pairs strong growth with a technical consolidation setup above defined support; watch resistance for a potential volume breakout.
Yahoo · Sep 11, 2026
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Yahoo · Sep 10, 2026
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
